AstraZeneca Results Presentation Deck

Appendix: 'What's next' Next key milestone by project Oncology Project adavosertib ceralasertib oleclumab imaradenant (formerly AZD4635) AZD5305 MEDI5752 AZD4573 AZD2811 AZD5991 AZD0466 Status as of 29 July 2021. 38 Target WEE1 ATR CD73 A2AR PARP1 PD-1/ CTLA4 CDK9 Aurora B MCL1 Bcl-2/xL Phase || || || || I | 1/11 | I 1/11 Indication uterine, ovarian cancer solid tumours blood cancers solid tumours solid tumours solid tumours solid tumours blood cancers solid tumours blood cancers blood cancers Next milestone Phase III start Phase II data Phase II data H2 2021 Phase II data Phase I data Phase II start 2021 Phase I data H2 2021 Phase II data Phase II start 2021 Phase II data BioPharmaceuticals: CVRM Target GLP-1/ glucagon Project cotadutide AZD4831 AZD5718 AZD9977 + Farxiga zibotentan + Farxiga AZD2693 AZD8233 MEDI3506 AZD1402 AZD0449 AZD4604 MPO MEDI7352 FLAP MCR + SGLT2 ETR + SGLT2 PNPLA3 PCSK9 IL33 IL4Ra JAK Phase NGF TNF || || || || || I || BioPharmaceuticals: Respiratory & Immunology | || || I Indication || NASH DKD HFpEF CKD CAD HF with CKD CKD NASH hypercholesterolaemia COPD asthma, AD, COVID-19, DKD asthma asthma pain Next milestone Phase II data H2 2021 Phase II data H2 2022 Phase II start H2 2021 Phase II data H2 2022 Phase II data H2 2022 Phase II data H2 2022 Phase I data H1 2022 Phase II data H2 2021 Phase I data H2 2021 Phase II data H2 2021/ 2022/2022+ Phase II data H2 2022 Phase II start H2 2021 Phase I start H2 2021 Phase II data H2 2022 3

View entire presentation